004310 Stock Chart & Stats
₩5070.00
₩160.00(3.26%)
―
--
Day’s Range― - ―
52-Week Range₩3,500.00 - ₩15,960.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)6.64M
Market Cap
₩151.80B
Enterprise ValueN/A
Total Cash (Recent Filing)₩18.72B
Total Debt (Recent Filing)₩49.91B
Price to Earnings (P/E)32.5
Beta0.66
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)162.84
Shares Outstanding32,000,000
10 Day Avg. Volume6,270,242
30 Day Avg. Volume6,636,404
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)1.17
Price to Sales (P/S)0.50
P/FCF Ratio-20.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
004310 FAQ
What was Hyundai Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Hyundai Pharmaceutical Co., Ltd. lowest stock price was ₩3500.00 and its highest was ₩15960.00 in the past 12 months.
What is Hyundai Pharmaceutical Co., Ltd.’s market cap?
Hyundai Pharmaceutical Co., Ltd.’s market cap is ₩151.80B.
When is Hyundai Pharmaceutical Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Hyundai Pharmaceutical Co., Ltd.’s earnings last quarter?
Hyundai Pharmaceutical Co., Ltd. released its earnings results on Jul 15, 2026. The company reported ₩39.199 earnings per share for the quarter, beating the consensus estimate of N/A by ₩39.199.
Is Hyundai Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Hyundai Pharmaceutical Co., Ltd.’s price is currently Undervalued.
Does Hyundai Pharmaceutical Co., Ltd. pay dividends?
Hyundai Pharmaceutical Co., Ltd. does not currently pay dividends.
What is Hyundai Pharmaceutical Co., Ltd.’s EPS estimate?
Hyundai Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hyundai Pharmaceutical Co., Ltd. have?
Hyundai Pharmaceutical Co., Ltd. has 32,000,000 shares outstanding.
What happened to Hyundai Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Hyundai Pharmaceutical Co., Ltd. reported an EPS of ₩39.199 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 10.544%.
Which hedge fund is a major shareholder of Hyundai Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in KR:004310
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hyundai Pharmaceutical Co., Ltd.
Headquartered in Seoul, South Korea, Hyundai Pharmaceutical Co., Ltd. is an international manufacturer and distributor of a diverse portfolio that includes pharmaceutical products, health food beverages, and medical equipment. The company's extensive offerings comprise both prescription (ETC) and over-the-counter (OTC) remedies, addressing a broad spectrum of therapeutic areas. These encompass conditions related to cardiovascular health, infectious diseases, the central nervous system, pain management, respiratory ailments, dermatological issues, digestive and endocrine system disorders, gynecological health, and ophthalmic care. Additionally, their range extends to nutritional supplements, diagnostic reagents, wound healing solutions, and treatments for allergies, arthritis, and anemia, among many others. The company was founded in 1965.
Daewon Pharmaceutical Co., Ltd
―
YUNGJIN PHARM. CO. LTD
―
Samjin Pharmaceutical Co., Ltd.
―
KOREA UNITED PHARM, INC.
―
Reyon Pharmaceutical Co., Ltd.
―